1. Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China.
- Author
-
Xu, Guo-fa, Liu, Li-min, Wang, Man, Zhang, Zhi-bo, Xie, Jun-dan, Qiu, Hui-ying, and Chen, Su-ning
- Subjects
- *
LYMPHOBLASTIC leukemia , *ACUTE leukemia , *CELLULAR therapy , *LEUKOCYTE count , *HEMATOPOIETIC stem cell transplantation - Abstract
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype of ALL. We retrospectively studied 70 cases with Ph-like ALL and here present the largest study of CAR-T cell treatment and haplo-HSCT for this leukemia. Median age was 26 years and median leukocyte count was 31.44 × 109/L. The proportion of patients receiving chemotherapy, KIs, CAR-T cells, and allo-HSCT was 19%, 30%, 46%, and 61%, respectively. The overall response rate was 62%, 73%, and 100% after one month of KI treatment combined with chemotherapy, CAR-T cell therapy, and allo-HSCT, respectively. Five-year DFS and OS were 35% and 51%, respectively. The five-year cumulative incidence of relapse and non-relapse mortality was 63% and 11%, respectively. Allo-HSCT was associated with a better DFS (p = 0.010) and OS (p = 0.000) by univariate analysis. In conclusion, allo-HSCT after KIs together with chemotherapy or CAR-T cell therapy is a safe and feasible treatment modality for Ph-like ALL. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF